Medytox is working to enter the U.S. market with its next-generation botulinum toxin product, which technology has been reverted to the company after being transferred to a foreign company.

On the 27th, Medytox announced that it has filed a biological license application (BLA) to the U.S. Food and Drug Administration (FDA) for its next-generation non-animal liquid botulinum toxin, MT10109L. Medytox has submitted a Biologics License Application (BLA) to the FDA for MT10109L for the treatment of moderate-to-severe frown lines and crow's feet.

MT10109L is characterized by the lack of use of animal-derived ingredients throughout the entire manufacturing process, including strain culture and